PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy
M J Fidler , L E Morrison , S Basu , L Buckingham
British Journal of Cancer 105 ( 12) 1920 -1926
19
2011
Novel Autoantibodies Biomarkers Panel to Prognosticate the Clinical Outcomes in Advanced-stage NSCLC Patients Receiving Anti PD-1/PD-L1 Immunotherapy
I Tarhoni , C Fhied , J A Borgia , M J Fidler
American Journal of Clinical Pathology 154
2020
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst , Paul Baas , Dong-Wan Kim , Enriqueta Felip
The Lancet 387 ( 10027) 1540 -1550
5,745
2016
Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.
Makoto Nishio , Yi-Long Wu , Fabrice Barlesi , Jin Seok Ahn
Journal of Clinical Oncology 42 ( 16_suppl) 8006 -8006
2024
Phase 1/2a, open‐label, multicenter study of RM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma
David M Cognetti , Jennifer M Johnson , Joseph M Curry , Samith T Kochuparambil
Head & neck 43 ( 12) 3875 -3887
79
2021
Praluzatamab ravtansine, a CD166-targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial
Valentina Boni , Mary J Fidler , Hendrik-Tobias Arkenau , Alexander Spira
Clinical Cancer Research 28 ( 10) 2020 -2029
23
2022
A definitive prognostication system for patients with thoracic malignancies diagnosed with coronavirus disease 2019: an update from the TERAVOLT registry
Jennifer G Whisenant , Javier Baena , Alessio Cortellini , Li-Ching Huang
Journal of Thoracic Oncology 17 ( 5) 661 -674
17
2022
Coronavirus disease 2019 outcomes, patient vaccination status, and cancer-related delays during the omicron wave: a brief report from the TERAVOLT analysis
Christine M Bestvina , Jennifer G Whisenant , Valter Torri , Alessio Cortellini
JTO Clinical and Research Reports 3 ( 8) 100335 -100335
16
2022
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
Thomas John , Christian Grohé , Jonathan W Goldman , Frances A Shepherd
Journal of Thoracic Oncology 18 ( 9) 1209 -1221
12
2023
An explorary analysis of a COVID-truncated REPLATINUM phase 3 trial in SCLC.
Alberto Chiappori , Mary J Fidler , Muhammad A Salamat , Tony R Reid
Journal of Clinical Oncology 39 ( 15_suppl) e20594 -e20594
2
2021
Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.
Paul Swiecicki , Yuefen Tang , Alexander T Pearson , Jameel Muzaffar
Journal of Clinical Oncology 39 ( 15_suppl) TPS6094 -TPS6094
1
2021
Associations between longitudinal pretreatment BMI and neutrophil/lymphocyte ratio (NLR) and progression-free (PFS) and overall survival (OS) in advanced NSCLC patients treated with single agent anti-PD-1/anti-PDL1 monoclonal antibodies (mAbs).
Megan Randall , Sanjib Basu , Revathi Kollipara , Marta Batus
Journal of Clinical Oncology 39 ( 15_suppl) e21189 -e21189
1
2021
N-cadherin, E-cadherin, ERCC1, c-kit, and IGFR1 expression in small cell lung cancer (SCLC) and potential for new therapeutic targets
Marta Batus , Ronald Myint , John Coon , Sanjib Basu
IASLC 2 191 -191
1
2009
A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
Alexander T Pearson , Tanguy Y Seiwert , Roger B Cohen , Nabil F Saba
Journal of Clinical Oncology 42 ( 16_suppl) 6008 -6008
2024
Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta‐Analysis of Observational Studies and Randomized Controlled Trials
Akash Sharma , Grace Alexander , Jian H Chu , Artemis Markopoulos
Journal of the American Heart Association e032620 -e032620
2024
Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) Patient Population With Locally Advanced Non-small Cell Lung Cancer
Yu M Zhou , Jacob Shin , Michael Jelinek , Mary J Fidler
Cureus 14 ( 9)
2022
Evaluation Of Impact Of Cardio-oncology Department On Cardiovascular Outcomes And Oncology Treatment: A Single Center Cross-sectional Retrospective Chart Review
Maharshi Joshi , Kelsey Danley , Melanie Rosado , Annabelle Santos Volgman
Circulation: Cardiovascular Quality and Outcomes 15 ( Suppl_1) A204 -A204
2022
OA10. 02 Psychosocial Distress in Patients with Driver-Mutant Lung Cancer
Lia Head , Nicole Yun , Sanjib Basu , Lauren Rynar
Journal of Thoracic Oncology 16 ( 10) S864 -S864
2021
Blood-based biomarker analysis in high PD-L1 expressing NSCLC treated with PD-1/PD-L1 based therapy with or without the addition of platinum-based chemotherapy.
Mary J Fidler , Victoria Meucci Villaflor , Amol Rao , Balazs Halmos
Journal of Clinical Oncology 39 ( 15_suppl) TPS9126 -TPS9126
2021
Retreatment with Platinum-Based Regimen for Patients with Metastatic NSCLC Is a Reasonable Therapy
Rachel L Mitchell , Mary J Fidler , Sanjib Basu , Philip Bonomi
JOURNAL OF THORACIC ONCOLOGY 10 ( 9) S420 -S420
2015